摘要:
The invention provides epsilon toxin (ETX) produced by Clostridium perfringens type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin-logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).
摘要:
An enzyme which cleaves at the sequence LPXTGX (SEQ ID NO:1) of the surface proteins of gram positive bacteria is provided. The enzyme was isolated from a group A Streptococcus. In addition, a method of detecting the enzyme, a method of isolating the enzyme, and methods of inhibiting the enzyme are disclosed. The figure is a schematic illustrating the positioning of the surface protein in the bacterial membrane, and the cleavage step which leads to infective bacteria.
摘要:
The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
摘要:
The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus , and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.